par Damien, Charlotte ;Leitinger, Markus;Kellinghaus, Christoph;Strzelczyk, Adam;De Stefano, Pia;Beier, Christoph Patrick;Sutter, Raoul;Kämppi, Leena;Strbian, Daniel;Taubøll, Erik;Rosenow, F.;Helbok, Raimund;Rüegg, Stephan;Damian, Maxwell;Trinka, E.;Gaspard, Nicolas
Référence BMC neurology, 24, 1, 19
Publication Publié, 2024-12
Référence BMC neurology, 24, 1, 19
Publication Publié, 2024-12
Article révisé par les pairs
Résumé : | Background: Status Epilepticus (SE) is a common neurological emergency associated with a high rate of functional decline and mortality. Large randomized trials have addressed the early phases of treatment for convulsive SE. However, evidence regarding third-line anesthetic treatment and the treatment of nonconvulsive status epilepticus (NCSE) is scarce. One trial addressing management of refractory SE with deep general anesthesia was terminated early due to insufficient recruitment. Multicenter prospective registries, including the Sustained Effort Network for treatment of Status Epilepticus (SENSE), have shed some light on these questions, but many answers are still lacking, such as the influence exerted by distinct EEG patterns in NCSE on the outcome. We therefore initiated a new prospective multicenter observational registry to collect clinical and EEG data that combined may further help in clinical decision-making and defining SE. Methods: Sustained effort network for treatment of status epilepticus/European Academy of Neurology Registry on refractory Status Epilepticus (SENSE-II/AROUSE) is a prospective, multicenter registry for patients treated for SE. The primary objectives are to document patient and SE characteristics, treatment modalities, EEG, neuroimaging data, and outcome of consecutive adults admitted for SE treatment in each of the participating centers and to identify factors associated with outcome and refractoriness. To reach sufficient statistical power for multivariate analysis, a cohort size of 3000 patients is targeted. Discussion: The data collected for the registry will provide both valuable EEG data and information about specific treatment steps in different patient groups with SE. Eventually, the data will support clinical decision-making and may further guide the planning of clinical trials. Finally, it could help to redefine NCSE and its management. Trial registration: NCT number: NCT05839418. |